Traditional views attribute the role of Omega-3 fatty acids (EPA/DHA) to "anti-inflammatory" effects—specifically, by competitively inhibiting arachidonic acid (AA) metabolism into pro-inflammatory prostaglandins and leukotrienes. However, functional medicine now understands Omega-3 at the deeper level of "inflammation resolution."
Research by Harvard University's Professor Charles Serhan found that EPA and DHA are enzymatically converted into a series of pro-resolving mediators (SPMs) during the late phase of inflammation: resolvins (E-series from EPA, D-series from DHA), protectins, and maresins. These mediators actively promote inflammation resolution by clearing apoptotic cells, inhibiting neutrophil infiltration, and enhancing tissue repair.
This discovery reshapes our understanding of chronic inflammation: it is not merely "excessive inflammation," but rather "insufficient resolution." Omega-3 fatty acids provide the synthetic substrates for SPMs, enabling the body to complete the full cycle from inflammation to repair.
When choosing a supplement, rTG (re-esterified triglyceride) fish oil offers significantly better bioavailability than EE (ethyl ester) forms. In rTG, EPA/DHA are re-esterified into natural triglycerides, resulting in approximately 70% higher absorption compared to EE. Krill oil contains EPA/DHA in phospholipid form, which integrates directly into cell membranes for superior bioavailability.
Dynas Group (HK) offers two Omega-3 solutions in the Immune Resilience Series: high-EPA/DHA rTG fish oil and krill oil. Both are available as softgels or liquids with customizable formulations. Our formulas go beyond EPA/DHA levels to fully support the entire pathway of inflammation resolution mediators.
